Differences in the entire nucleotide sequence between hepatitis B virus genomes from carriers positive for antibody to hepatitis B e antigen with and without active disease

✍ Scribed by Minoru Horikita; Susumu Itoh; Kayoko Yamamoto; Takao Shibayama; Fumio Tsuda; Dr. Hiroaki Okamoto

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 930 KB
• Volume: 44
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890440118

✦ Synopsis

Abstract

The entire nucleotide sequence was determined for eight hepatitis B virus (HBV) genomes from three symptom‐free carriers, two patients with chronic persistent hepatitis and one patient with chronic active hepatitis, who were positive for antibody to hepatitis B e antigen (HBeAg). The two patients with chronic persistent hepatitis were tested again after they developed chronic active or fulminant hepatitis, making a total of eight samples. Six had a point mutation in the preC region prohibiting the encoding of HBeAg precursor, while the remaining two had a deletion of 8 or 21 nucleotides within the X gene upstream of the preC transcription initiation sites which would affect the X gene and the putative preC/C promoter. Most genomes from the three symptom‐free carriers and the two patients with chronic persistent hepatitis, with HBV DNA levels of 10^2^–10^3^/ml, had deletion, frameshift mutation, initiation failure or a premature stop codon, rendering them replication‐incompetent. In contrast, such mutations were rarely seen in HBV genomes from the two patients with chronic persistent hepatitis after they had developed active or fulminant hepatitis and from the patient with chronic active hepatitis, all of whom had vigorous HBV replication with serum HBV DNA from 10^6^ to 10^9^/ml. Unique mutations for amino acid changes were more frequent in HBV genomes with a higher replicative activity. These results indicate two kinds of HBV genomes with an HBeAg‐minus phenotype, one with defects seriously affecting viral replication and the other without such defects, which would account for different clinical profiles in carriers with antibody to HBeAg. © 1994 Wiley‐Liss, Inc.